Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. RESULTS: Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33% [3.6 mmol/mol]; 1.2 mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01). CONCLUSIONS: In a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a potential risk of severe hypoglycemia if persons with DM do not appropriately reduce the prandial insulin dosage.1171–1174”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“The amylin analog pramlintide, the only other medication approved for the treatment of T1D, is administered with prandial insulin.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“A1C reductions are consistently modest, and mild weight loss is common.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Tachyphylaxis is often seen after several years of therapy.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Nausea is a common adverse effect.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 4×
“At 26 weeks, significantly more subjects receiving liraglutide 1.8 mg compared with placebo achieved the ADA target of HbA1c,7.0% (,53.0mmol/mol) (18.8 vs. 10.0%, respectively, odds ratio [OR] 2.12 [95% CI 1.11; 4.06], P = 0.0231) (Fig.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E. H. M., Wolffenbuttel, B. H. R., & Niessen, L. W. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.458 · Cited by 565
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Furthermore, liraglutide decreases food intake (9) and has weight loss benefits in type 2 diabetes (10–14).”
BackgroundBradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Self-citationTemporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Group, T. D. C. A. C. T. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1711 · Cited by 205
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Self-citationKapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Bae, J. P., Lage, M. J., Mo, D., Nelson, D. R., & Hoogwerf, B. J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.11.016 · Cited by 136 · cited 1×
“8% of people with type 1 diabetes are obese (3).”
BackgroundLiraglutide as additional treatment for type 1 diabetes
Varanasi, A., Bellini, N., Rawal, D., Vora, M., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0330 · Cited by 129
The role of glucagon on type 2 diabetes at a glance
Godoy‐Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 112 · cited 1×
“In people with type 2 diabetes, liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is known to stimulate insulin secretion, improve b-cell function, and inhibit glucagon release froma-cells in a glucose-dependent manner (8).”
BackgroundFrandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges
Davies, M. J. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802745 · Cited by 101 · cited 1×
“cause of reasons such as concern about hypoglycemia and/or weight gain (2).”
BackgroundKuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 79
Colburn, W. A., Gottlieb, A. B., Koda, J., & Kolterman, O. G. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04147.x · Cited by 60 · cited 1×
“However, the evidence base for such treatments is limited (5), and only pramlintide, an analog of human amylin (6), is currently approved by the U.”
BackgroundBode, B. W., & Garg, S. K. (2015) · Endocrine Practice · doi:10.4158/ep15869.ra · Cited by 56 · cited 1×
“However, the evidence base for such treatments is limited (5), and only pramlintide, an analog of human amylin (6), is currently approved by the U.”
BackgroundPotential role of non‐insulin adjunct therapy in Type 1 diabetes
George, P., & McCrimmon, R. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03744.x · Cited by 51
Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
Harrison, L. B., Mora, P. F., Clark, G. O., & Lingvay, I. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318279b7d6 · Cited by 46
Pieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J., & Heller, S. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 43
Self-citationTraina, A. N., Lull, M. E., Hui, A. C., Zahorian, T. M., & Lyons-Patterson, J. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.10.006 · Cited by 40
Emoto, M., Terauchi, Y., Ozeki, A., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0401 · Cited by 29
Hendrychova, T., Vytrisalova, M., Smahelova, Vlček, J., & Kubena (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s47750 · Cited by 25
Mathieu, C., Zinman, B., Hemmingson, J. U., Woo, V. C., Colman, P. G., Christiansen, E., Linder, M., & Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)44999-7 · Cited by 7
Self-citation
Research works printed but not linked: 3
- FDA, 2005, New diabetes drug, FDA Consum, 39, 3
- 2013, Kidney Disease: Improving Global Outcomes. Definition and classification of CKD, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 3, 19
- Østergaard, 2015, Effects of liraglutide as add-on to insulin on counter-regulatory hormone responses, gastric emptying and glycaemic recovery during hypoglycaemia (Abstract), Diabetologia, 58, A963
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“Addition of liraglutide, either in a treat-to-target trial design or on top of capped insulin regimens, resulted in weight loss and reduction in insulin dose, but only modest reduction in A1c, and increased rates of gastrointestinal adverse events (AEs), ketoacidosis, and symptomatic hypoglycemia (Ahrén et al., 2016;…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“4% [2–4 mmol/mol]), decreases in weight ( 5 kg), and reductions in insulin doses (257,258).”
Self-citation
Metadata
- Authors
- Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., Buse, J. B., & for the ADJUNCT TWO Investigators
- Affiliations
- Lund University, Lund, Sweden
- University of Washington (US)
- Medical University of Graz (AT)
- KU Leuven (BE)
- Hospital General de Segovia, Segovia, Spain
- Aarhus University Hospital (DK)
- University of Cape Town (ZA)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-04
- Volume
- 39
- Issue
- 10
- Pages
- 1693-1701
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2494601841
- Cited by
- 262
- References
- 36
- Citations by year
- 2026: 38 · 2025: 49 · 2024: 33 · 2023: 25 · 2022: 16 · 2021: 23 · 2020: 29 · 2019: 11 · 2018: 21 · 2017: 10 · 2016: 7
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, GLP-1 receptor agonists, HbA1c, glycemic control, weight loss, insulin dose reduction, hypoglycemia, diabetic ketoacidosis, quality of life
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.